Clinical Question
How have the regulatory landscape and safety profiles of semaglutide and other compounded peptides changed as of late 2026?
Evidence Snapshot
- Semaglutide: FDA-approved (Ozempic, Wegovy, Rybelsus); shortage-related compounding period has ended.
- BPC-157: Reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC) in July 2026; classified as a Category 2 bulk substance.
- KPV: Nomination withdrawn; reviewed by PCAC in July 2026 for potential 503A Bulks List inclusion.
- Growth Hormone Secretagogues: GHRP-2, GHRP-6, and MK-677 remain in Category 2 due to immunogenicity and safety concerns.
- Safety Signals: Emerging signals for semaglutide include NAION, pulmonary aspiration, and intestinal obstruction.
What the Research Shows
Data from September 2026 indicate a significant shift in the availability of compounded semaglutide. The national shortage-related enforcement discretion has concluded. Patient-specific compounding under Section 503A is now subject to restrictions against regularly compounding drugs that are essentially copies of commercially available approved drugs. Furthermore, the FDA has proposed excluding semaglutide from the 503B Bulks List due to a lack of identified clinical need. FDA alerts emphasize that semaglutide sodium and acetate are not the active ingredients used in approved products and lack a known lawful basis for compounding.
Several other compounds have undergone recent regulatory review. BPC-157 and KPV were both reviewed by the Pharmacy Compounding Advisory Committee in July 2026. BPC-157 was previously designated as an FDA Category 2 bulk substance due to potential safety risks involving immunogenicity, impurities, and limited human safety data. KPV, which also had its nomination withdrawn at one stage, remains under review for the 503A Bulks List despite limited human exposure information.
Safety data from the FDA Adverse Event Reporting System (FAERS) for semaglutide show strong signals for gastrointestinal issues, including nausea and vomiting. More severe emerging signals include NAION (96 cases through December 2024), which is under EMA review as of January 2025. Additionally, pulmonary aspiration risk has been added to the Ozempic label in 2025, particularly concerning for patients undergoing general anesthesia due to delayed gastric emptying.
Mechanism
The provided data focuses on regulatory status and adverse event signals; specific biochemical mechanisms of action for the referenced compounds were not included in the source records.
Limitations of the Evidence
The primary limitation across multiple compounds is the lack of human safety data. For BPC-157, the FDA specifically notes concerns regarding API characterization and peptide-related impurities. Safety signals for semaglutide, such as suicidal ideation, are currently under evaluation; present data do not support a higher risk compared to background rates. Additionally, the regulatory status for compounds like GHRP-2 and GHRP-6 is based on immunogenicity concerns rather than specific clinical trial failures. Some compounds, such as Thymosin Alpha 1, showed negative results in Phase III trials (NCT02867267), failing to reduce mortality in sepsis.
Clinical Takeaway
Compounding options for semaglutide have narrowed following the end of its national shortage, with the FDA clarifying that salt forms (sodium/acetate) are not recognized for lawful compounding. Multiple peptides including Melanotan II and LL-37 remain in Category 2, indicating they may present significant safety risks. Physicians monitoring patients on approved GLP-1 RAs should be aware of emerging postmarketing safety signals, including NAION and pulmonary aspiration.
Sources
- FDA: Certain bulk drug substances that may present significant safety risks (2023-2026).
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting.
- FAERS Safety Data (2023-2025).
- NCT03548935 (STEP 1); NCT03574597 (SELECT); NCT02867267 (Sepsis).
- FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
For physicians evaluating the regulatory status of these compounds, it is essential to understand how to find a peptide prescriber who adheres to current FDA 503A and 503B compounding regulations. You can search for qualified clinical facilities via our peptide therapy near me directory.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.